Australia is carefully awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://giant-bike274818.bloggerpal.com/312678/retatrutide-australia-a-new-breakthrough-for-obesity-treatment